Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy’s is placing generic semaglutide and biosimilars at the centre of its growth strategy.

Focus areas for expansion

The company’s strategy identifies generic semaglutide and biosimilars as important areas for future growth. The approach reflects a focus on expanding through these two segments.

Strategic significance

By prioritising both products, Dr Reddy’s is defining the areas it intends to rely on to support its growth ambitions. The available information does not provide further details on development plans, timelines or expected financial contributions.

For now, generic semaglutide and biosimilars represent the company’s stated strategic focus.